Frontage announces the promotion of Dr. Wentao Zhang as Chief Strategy Officer
Frontage Laboratories Inc., today announced that Dr. Wentao Zhang has been promoted to Chief Strategy Officer and will continue to report to Dr. Abdul Mutlib, Chief Executive Officer.
Dr. Zhang has been a member of Frontage’s executive team where he successfully led global restructuring and the growth of the Drug Discovery and Chemistry business. Dr. Zhang came to Frontage Laboratories in 2021 through the acquisition of Quintara Discovery, an innovative and highly profitable niche services organization based in the bay area, California, USA, he founded in 2012. In his new role, Dr. Zhang will be responsible for Frontage’s comprehensive end-to-end services in drug discovery, preclinical safety and toxicology, and pharmaceutical development.
“Our Chairman, Dr. Song Li and I see a great potential in Wentao’s leadership in growing and expanding Frontage’s business globally and help us reach our vision of becoming a one billion revenue organization by 2028. We have complete confidence in Wentao’s ability to help grow the preclinical and pharmaceutical development services to the next level,” said Dr. Abdul Mutlib, CEO.
“I am excited and humbled to take on this new role and sincerely appreciate the trust placed on me by our Chairman, CEO and rest of my colleagues. Since I joined Frontage, I’ve had an incredible opportunity to meet and work with many talented people. Our people are our most valuable assets. I am also amazed by the rapid growth of Frontage and its broad range of services offered. I feel confident that Frontage will continue to grow despite the current headwinds in the global biotech industry. I am looking forward to working with our team members, our customers, and our collaborators” expressed Dr. Zhang.